Rivorax

# Rivorax ## Overview - **Classification**: Novel Broad-Spectrum Antibiotic (Pyridone-Quinolone Class) - **Mechanism**: Inhibits bacterial DNA gyrase and topoisomerase IV, crucial enzymes for bacterial DNA replication, transcription, repair, and recombination. ## Primary Indications 1. **Complicated Urinary Tract Infections (cUTI)** - Including pyelonephritis. 2. **Community-Acquired Bacterial Pneumonia (CABP)** - Treatment of adult patients. 3. **Acute Bacterial Skin and Skin Structure Infections (ABSSSI)** - Treatment of adult patients. ## Adult Dosing ### Standard Dosing **Complicated Urinary Tract Infections (cUTI)** - **Dose**: **300 mg** - **Frequency**: Once daily - **Route**: Oral (PO) - **Duration**: 7 days **Community-Acquired Bacterial Pneumonia (CABP) / ABSSSI** - **Dose**: **600 mg** - **Frequency**: Once daily - **Route**: Intravenous (IV) or Oral (PO) - **Duration**: 5 to 10 days (clinical judgment) ### Dose Adjustments - **Renal Impairment**: - CrCl 30-60 mL/min: **450 mg** once daily. - CrCl <30 mL/min (including hemodialysis/CAPD): **300 mg** once daily. Administer after dialysis on dialysis days. - **Hepatic Impairment**: - Moderate to severe (Child-Pugh B or C): Consider dose reduction to **300 mg** once daily. - **Elderly Patients**: No specific adjustment beyond renal function. Monitor for increased adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **5 mg/kg/dose** - **Frequency**: Every 24 hours - **Maximum**: **100 mg/dose** - **Special Notes**: Use only if no alternative exists due to potential for cartilage damage. Monitor closely. ### Infants (1-12 months) - **Dose**: **8 mg/kg/dose** - **Frequency**: Every 24 hours - **Maximum**: **150 mg/dose** ### Children (1-12 years) - **Dose**: **10 mg/kg/dose** - **Frequency**: Every 24 hours - **Maximum**: **300 mg/dose** for cUTI; **600 mg/dose** for CABP/ABSSSI. ### Adolescents (13-18 years) - **Dose**: Transition to adult dosing, typically **600 mg** - **Frequency**: Once daily - **Maximum**: **600 mg/dose** ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Rivorax or other quinolones. - **Absolute**: History of QTc prolongation or Torsades de Pointes. - **Absolute**: Concomitant use with Class IA or III antiarrhythmics. - **Absolute**: History of tendinopathy or tendon rupture associated with fluoroquinolone use. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, Diarrhea, Headache. - **Common (1-10%)**: Dizziness, Insomnia, Rash, Elevated liver enzymes (ALT/AST). - **Serious but Rare**: Tendinopathy/tendon rupture, QTc prolongation, **_Clostridioides difficile_** infection (CDI), Peripheral neuropathy, Hypersensitivity reactions (anaphylaxis, SJS). ### Key Drug Interactions - **Antacids/Multivitamins (containing polyvalent cations like Aluminum, Magnesium, Iron, Zinc)**: Significantly reduced absorption of Rivorax. Administer Rivorax **2 hours before or 6 hours after** these agents. - **QTc-prolonging drugs (e.g., Amiodarone, Sotalol, Cisapride, Macrolides, TCAs)**: Increased risk of Torsades de Pointes. Avoid concomitant use. - **Warfarin**: May potentiate anticoagulant effect, increasing INR. Monitor INR closely, adjust warfarin dose as needed. - **Corticosteroids**: Increased risk of tendon rupture. Use with caution, especially in elderly. ## Monitoring & Follow-up - **Before Treatment**: Baseline ECG (for QTc interval), Liver Function Tests (LFTs), Renal function (CrCl). - **During Treatment**: Monitor for signs/symptoms of tendinopathy or neuropathy. ECG monitoring for patients with risk factors for QTc prolongation. Monitor LFTs if therapy is prolonged. - **Clinical Signs**: Report tendon pain/swelling, numbness/tingling, muscle weakness, severe diarrhea, or new arrhythmias immediately. ## Clinical Pearls - 💡 **Tip 1**: Administer Rivorax with food to help minimize gastrointestinal upset. - 💡 **Tip 2**: Advise patients to stay well-hydrated and avoid excessive sun exposure due to potential photosensitivity. - 💡 **Tip 3**: Counsel patients to report any joint pain, swelling, or unusual tingling/numbness immediately; discontinue Rivorax if these symptoms occur. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.